Akèy › Rabdomiyosakòm › Texas › Houston

Etid klinik pou Rabdomiyosakòm nan Houston, TX

6 etid pou Rabdomiyosakòm ap chèche patisipan nan sit nan ak bò kote Houston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

Ap rekriteFaz 1

University of Texas - MD Anderson Cancer Center, Houston

24 Months – 18 Years · Tout sèks · Mizajou Sep 25, 2026 · NCT06441331

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

Ap rekriteFaz 1

Texas Children's Hospital, Houston

Laj 1 a 21 · Tout sèks · Mizajou Aug 6, 2026 · NCT04715191

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

Ap rekriteFaz 1/2

Texas Children's Hospital, Houston

Laj 1 a 30 · Tout sèks · Mizajou Jul 22, 2026 · NCT06721689

VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

Ap rekriteFaz 1/2

Texas Children's Hospital, Houston

6 Months – 30 Years · Tout sèks · Mizajou Jun 2, 2026 · NCT04796012

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

Ap rekriteFaz 1

Texas Children's Hospital, Houston

Laj 1 a 25 · Tout sèks · Mizajou Jan 22, 2026 · NCT04995003

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

Ap rekriteFaz 1

Houston Methodist Hospital, Houston

Jiska laj 21 · Tout sèks · Mizajou Nov 3, 2025 · NCT06198296

Etid Rabdomiyosakòm nan lòt vil

Lòt etid nan Houston

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.